Analyst Price Target is $158.50
▲ +1.34% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $158.50, with a high forecast of $175.00 and a low forecast of $142.00. The average price target represents a 1.34% upside from the last price of $156.41.
Current Consensus is
The current consensus among 2 investment analysts is to hold stock in Medpace. This rating has held steady since June 2022, when it changed from a Buy consensus rating.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.